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Background: Many cancers show aberrant silencing of gene expression and overexpression of histone
methyltransferases. The histone methyltransferases (HKMT) EZH2 and EHMT2 maintain the repressive chromatin
histone methylation marks H3K27me and H3K9me, respectively, which are associated with transcriptional
silencing. Although selective HKMT inhibitors reduce levels of individual repressive marks, removal of H3K27me3
by specific EZH2 inhibitors, for instance, may not be sufficient for inducing the expression of genes with
multiple repressive marks.
Results: We report that gene expression and inhibition of triple negative breast cancer cell growth (MDA-MB-231) are
markedly increased when targeting both EZH2 and EHMT2, either by siRNA knockdown or pharmacological inhibition,
rather than either enzyme independently. Indeed, expression of certain genes is only induced upon dual inhibition. We
sought to identify compounds which showed evidence of dual EZH2 and EHMT2 inhibition. Using a cell-based assay,
based
on the substrate competitive EHMT2 inhibitor BIX01294, we have identified proof-of-concept compounds that
induce re-expression of a subset of genes consistent with dual HKMT inhibition. Chromatin immunoprecipitation
verified a decrease in silencing marks and an increase in permissive marks at the promoter and transcription start
site of re-expressed genes, while Western analysis showed reduction in global levels of H3K27me3 and H3K9me3.
The compounds inhibit growth in a panel of breast cancer and lymphoma cell lines with low to sub-micromolar
IC50s. Biochemically, the compounds are substrate competitive inhibitors against both EZH2 and EHMT1/2.
Conclusions: We have demonstrated that dual inhibition of EZH2 and EHMT2 is more effective at eliciting
biological responses of gene transcription and cancer cell growth inhibition compared to inhibition of single
HKMTs, and we report the first dual EZH2-EHMT1/2 substrate competitive inhibitors that are functional in cells.Background
EZH2 along with EED and SUZ12 are the indispensible
core components of the Polycomb Repressive Complex
(PRC2) responsible for maintenance of the repressive
epigenetic mark H3K27me3: trimethylation of lysine
27 of histone 3 [1]. High expression of the histone
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article, unless otherwise stated.ated with gene amplification, has been well documented
in a variety of cancers [2], [3]. EZH2 overexpression has
been linked to poor prognosis [4, 5] and shown to be a
marker of aggressive breast cancer [6], associated with
difficult-to-treat basal or triple negative breast cancer [7].
Gene knockdown of EZH2 reduces growth of a variety of
tumour cell types [5, 8, 9]. Several groups have reported
specific co-factor competitive EZH2 inhibitors [10–16],
which have shown a strong capacity to reduce growth of
cells expressing mutated forms of EZH2 (such as certain
non-Hodgkin’s lymphoma [12]). However, removal of the
repressive mark H3K27me3 alone may not always beis distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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shown that highly specific EZH2 inhibitors require a mu-
tant EZH2 status to inhibit cell growth, being less effective
in cells solely expressing wild type EZH2 [5, 8, 9]. Elimin-
ation of further repressive methylation marks by inhibition
of additional HKMTs may be required to fully realise the
epigenetic potential of HKMT inhibitors.
EHMT2 (also known as G9a) and the highly homolo-
gous EHMT1 (also known as GLP) are HKMTs partly
responsible for mono- and di-methylation of lysine nine of
histone 3 (H3K9me1 and H3K9me2, respectively); re-
pressive chromatin marks found on the promoter re-
gions of genes that are often aberrantly silenced in
cancer [17]. EHMT2 is overexpressed and amplified in
various cancers including leukaemia, prostate carcin-
oma, and lung cancer, with gene knockdown of EHMT2
inhibiting cancer cell growth in these tumour types [18,
19]. BIX-01294 (see Fig. 2) was previously identified as
an inhibitor of the HKMTs EHMT2 and EHMT1, and
subsequent medicinal chemistry studies around the 2,
4-diamino-6, 7-dimethoxyquinazoline template of BIX-
01294 have yielded a number of follow-up EHMT2
inhibitors [20–25].
In addition to its role in methylating H3K9, EHMT2
has been shown to be able to methylate H3K27 [26,
27]. It has been suggested that this could provide cells
with a mechanism to compensate in part for a loss of
EZH2 [28]. The picture is further complicated by recent
evidence that EHMT2 and EZH2 (via the PRC2 com-
plex) interact physically and share targets for epigenetic
silencing [29]. Combining this evidence, it would again
suggest that specifically targeting either EZH2 or
EHMT2 alone may not be sufficient to reverse epigen-
etic silencing of genes, but rather combined inhibition
may be required. To this end, we have examined the
effect of dual EZH2 and EHMT2 gene knockdown or
enzyme inhibition in breast cancer cells. Consistent
with the requirement for removal of both repressive
H3K9 and H3K27 methylation marks, we show that
dual inhibition of EHMT2 and EZH2 pharmacologically
or by SiRNA is necessary for reactivation of certain
genes and induces greater inhibition of cell growth than
targeting either HKMT alone in triple negative breast
cancer MDA-MB-231 cells. Further, we have identified
proof-of-concept compounds which are dual (substrate
competitive) EZH2-EHMT1/2 inhibitors.
Results
Combined inhibition of EZH2 and EHMT2 is more
effective at inducing gene re-expression and inhibiting
tumour cell growth than single HKMT inhibition
SiRNA knockdown in the MDA-MB-231 breast tumour
cell line was used to examine the effect of combined in-
hibition of EZH2 and EHMT2 expression on epigeneticregulation at select target genes, compared to knockdown
of either gene alone (Fig. 1a). Knockdown of EZH2 with
two independent SiRNAs induced 2–4-fold increased
mRNA levels of KRT17 and FBXO32, genes which are
known to be silenced in an EZH2 dependent manner [30].
Knockdown of EHMT2 (G9a) had limited effects on
mRNA levels of these target genes. However, double
knockdown of EZH2 and EHMT2 had dramatic effects on
the level of SPINK1mRNA, a gene which was not upregu-
lated by silencing of EZH2 or EHMT2 individually. Thus,
for at least certain genes, dual reduction in EZH2 and
EHMT2 levels is necessary to observe marked changes in
target gene expression 48 h following knockdown.
The effects on gene expression of the selective EZH2
inhibitor GSK343 [10] and the selective EHMT2 inhibi-
tor UNC0638 [22] (Fig. 2) used alone or in combination
were also examined using the MDA-MB-231 triple
negative breast cancer cell line (Fig. 1b). When MDA-
MB-231 cells were treated with the EZH2 inhibitor
GSK343 at 1–15 μM for 48 h alone, there was little
change in the mRNA levels of KRT17, FBX032 and
SPINK1 and the H3K27 demethylase JMJD3 (Fig. 1b).
UNC0638 at 1–15 μM for 48 h alone showed dose-
dependent upregulation of FBX032 and JMJD3; however,
KRT17 and SPINK1 mRNA levels were not significantly
altered. However, the combination treatments with
GSK343 and UNC0638 showed marked increase in
mRNA levels of all the target genes, in contrast to the sin-
gle agent treatment. Consistent with dual EZH2/EHMT2
SiRNA knockdown, SPINK1 has the biggest change in
mRNA levels between the single and combination treat-
ments, having a 50-fold increase with the combination
treatment. Global levels of H3K27me3 and H3K9me3 in
MDA-MB-231 cells were examined following treatment
with GSK343 and UNC0638 as single agents and in
combination (Additional file 1: Figure S1). Together,
these data show a minor decrease in global levels of
these silencing marks following treatment with either
GSK343 or UNC0638 as single agents across a range of
doses yet a strong dose-dependent decrease in the levels
of these marks when cells are treated with these com-
pounds in combination. This provides further compelling
evidence for the efficacy of dual HKMT inhibition in
reversal of epigenetic silencing in cancer cells.
Next, the effects on cell viability of GSK343 and
UNC0638 used alone or in combination were examined
(Fig. 1c). Treatment alone with GSK343 showed no
significant reduction in cell viability up to 15 μM, while
UNC0638 sole treatment caused a dose dependant reduc-
tion in cell viability, with a calculated IC50 of 9 μM. When
the cells were treated with both compounds in combin-
ation, a marked increase in growth inhibition was observed
when compared to single agent treatment using UNC0638
or GSK343 (Fig. 1c). This is particularly apparent at a
Fig. 1 MTT and mRNA levels in MDA-MB-231 cells after pharmacological inhibition and siRNA knockdown of EZH2 and EHMT2(G9a), individually
and in combination. a Expression levels of KRT17, FBX032, JMJD3, EZH2, SPINK1 and EHMT2 were measured by qRT-PCR in the MDA-MB-231 cell
line 48 h after transfection with siRNAs targeting EZH2 and EHMT2, both individually and in combination. All measurements were normalised to
the fold-change (relative to GAPDH) in the mock transfection control. Error bars represent the mean ± SD of experiment performed in technical
triplicate. b Expression levels of KRT17, FBX032, JMJD3 and SPINK1 were measured by qRT-PCR in the MDA-MB-231 cell line treated for 48 h with
GSK343, UNC0638, and UNC0638 (at 7.5 μM) with increasing doses of GSK343. Each group has been compared to the untreated sample following
normalisation to GAPDH. Error bars represent the mean ± SD of experiment performed in technical triplicate. c MTT assay for cell viability of MDA-MB-
231 cells after treatment. MDA-MB-231 cells were seeded in 96 well plates. After 24 h, increasing doses of GSK343, UNC0638 or combination treatments
(1, 2.5, 5, 7.5, 10 and 15 μM) were added to cells. Control was media with 0.5 % DMSO. Cell viability was measured by MTT assay after a 48-h treatment
and a 24-h proliferation period. Error bars represent the mean ± SEM of five independent repeats
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have no significant effect on reducing cell viability, while in
combination, they markedly reduce cell viability to >50 %
(p < 0.01).
Analogues of an EHMT2-specific inhibitor can upregulate
EZH2 silenced genes
Both EZH2 and EHMT1/2 belong to the SET-domain
superfamily [31], the catalytic SET-domain being respon-
sible for the methylation of the targeted lysine residues.
BIX-01294 has previously been shown, both structurally
and biochemically, to bind to the substrate (histone)-
binding pocket of EHMT1/2 [32]. Since protein recogni-
tion motifs for histone binding at repressive sites are
similar [33] and EHMT2 has been shown to be able to
methylate H3K27, in addition to its more common
H3K9 target [27], it is likely that there are common as-
pects to the histone substrate binding pockets of therepressive HKMTs EZH2 and EHMT1/2. We therefore
felt it would be feasible to use quinazoline template of
BIX-01294 in the discovery of dual (substrate competi-
tive) EZH2-EHMT1/2 inhibitors.
A compound library based on the selective BIX-01294
EHMT2 inhibitor was synthesised and characterised
analogously to previously reported methods [20–22, 24,
25, 32]. In light of the reported selectivity of this chem-
ical scaffold towards EHMT1/2, the library was primarily
examined for compounds showing additional EZH2 in-
hibitory activity, as defined by re-expression of KRT17
and FBXO32, genes which are known to be silenced in
an EZH2 dependent manner [30]. The majority of com-
pounds had little or no effect on both KRT17 and
FBXO32 RNA levels. However, we identified three com-
pounds which upregulate KRT17 and FBXO32 RNA
levels. The data for these compounds along with a com-
parison of the related EHMT2 inhibitors BIX-01294 and
Fig. 2 Chemical structure of histone lysine methyltransferase inhibitors
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pounds are shown in Table 1 (for chemical structures see
Fig. 2 and the Additional file 2 for hit characterisation
data). All hit compounds—HKMTI-1-005, HKMTI-1-011,
HKMTI-1-022—showed upregulation of KRT17, FBXO32,
and JMJD3 mRNA at a 10 μM dose. The reported
EHMT2-specific inhibitors BIX-01294 and UNC0638,
while being closely related to our hits from a chemical
structure perspective, elicit different effects on expres-
sion of the target genes. BIX-01294 (Table 1, entry 4)
does not upregulate KRT17 but does upregulate
FBXO32. This is compatible with the observation that
FBXO32 is regulated via multiple mechanisms, poten-
tially responding to a variety of factors [34]. An analo-
gous effect is observed for UNC0638 (Table 1, entry 5).
The specific EZH2 inhibitor GSK343 has no effect
whatsoever on all the target genes studied (Table 1,Table 1 RT-PCR data for a single dose of a panel of HKMT
inhibitor compounds
Entry Compound KRT17 FBXO32 JMJD3 EZH2
1 Hit HKMTI-1-005 4.05 3.65 3.12 0.63
2 Hit HKMTI-1-022 4.28 29.4 11.56 0.21
3 Hit HKMTI-1-11 6.95 33.25 6.25 0.22
4 G9ai BIX01294 1.06 3.34 2.7 0.87
5 G9ai UNC0638a 1.1 5.5 3.4 0.4
6 EZH2i GSK343 0.9 1.2 1.0 1.0
7 Negative HKMTI-1-002 0.66 1.12 1.57 0.86
8 Negative HKMTI-1-012 1.32 1.06 0.9 1.38
9 Negative HKMTI-1-013 0.78 0.93 0.87 0.13
RNA levels for target genes are normalised against the housekeeping gene
GAPDH, and shown is the fold increase compared to the mock treated sample
aUNC0638 treatment at 7.5 μM, all other compounds given at 10 μMentry 6) when examined up to 72 h following treatment
and at concentrations up to 10 μM.
To further evaluate the three hit compounds identi-
fied, we treated MDA-MB-231 cells for 48 and 72 h at
various concentrations of compounds and examined
gene expression effects (Fig. 3a). All hit compounds
showed a dose-dependent increase of KRT17, FBXO32,
as well as JMJD3 mRNA. Higher doses of certain com-
pounds started to cause cell death, and because of this,
at these doses, the expression of KRT17 was often below
the detection limit of low-expressed genes.
Chromatin immunoprecipitation (ChIP) experiments
were carried out on treated MDA-MB-231 cells to
verify that the detected gene upregulation is indeed due
to chromatin remodelling (Fig. 3b). We tested the silen-
cing marks H3K9me3 and H3K27me3 as well as the
activating marks H3K4me3, H3K4me2, H3K27ac and
H3K9ac. All three compounds showed a clear decrease
in repressive chromatin marks (H3K27me3, H3K9me3),
and at least in some instances, an increase in permissive
marks, at two target genes (Fig. 3b). This is consistent with
the compounds having dual HKMT inhibitory activity in
removing both H3K9me and H3K27me marks, while
allowing activating marks to be established at these loci.
Genome-wide changes in gene expression
Agilent microarrays were used to perform gene expression
profiling in MDA-MB-231 breast cancer cells after 24 h of
treatment with the hit compound HKMTI-1-005, the
EZH2 inhibitor GSK343 [10] and EHMT2 inhibitor
UNC0638 [22]. To validate the finding of the initial ex-
pression data for the hit compounds, a second microarray
experiment was performed on the same platform using
HKMTI-1-005-treated MDA-MB-231 cells after 24 h of
treatment. To assess the extent to which our selected
Fig. 3 Effects of hit compounds on RNA levels and histone marks. a Sybr green real-time PCR mRNA level measurement of EZH2 target genes
and executing enzymes following a 48-h compound treatment at different concentrations of MDA-MB-231 cells. Measurements marked with an ‘*’ are
below detection limit, most likely due to cell death. All RT-PCR experiments were performed in triplicate, normalised to GAPDH and displayed as fold
difference to the untreated sample. Error bars represent the mean ± SD of experiment performed in technical triplicate. b Sybr green real-time PCR
measurement of the FBXO32 transcription start site and KRT17 promoter region following chromatin immunoprecipitation, using antibodies to the
histone marks shown, of MDA-MB-231 cells treated with three selected compounds at 5 μM for 72 h. Shown are representative examples of triplicate
ChIP experiments which consistently showed the same changes. The fold difference to the untreated sample is shown. Each IP-value has been
determined as the relative increase to the no-antibody control and then normalised to GAPDH levels
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tor BIX-01294—had gained EZH2 inhibitory activity,
lists of genes activated or repressed following siRNA
knockdown of EZH2 in MDA-MB-231 cells were identi-
fied [35] and shown in Additional file 3: Table S4. These
lists of target genes were investigated in the context of
genome-wide changes in gene expression following
treatment with the compounds. HKMTI-1-005 showed
very significant enrichment for upregulation of EZH2 si-
lenced genes (Fig. 4a) in both the initial array (p =
4.53x10−43) and the validation array (p = 1.99x10−49).
GSK343 and UNC0638 also both showed a significant
upregulation of EZH2 target genes (Fig. 4a) though to a
lesser extent than HKMTI-1-005. Indeed, analysis of
the difference in systematic upregulation showed that
HKMTI-1-005 upregulated EZH2-silenced genes sig-
nificantly more than either GSK343 (p = 5.8x10−5) or
UNC0638, (p = 1.7x10−4).The same enrichment tests were repeated using target
gene sets identified in an EZH2 siRNA knockdown
study in another breast cancer cell line, MCF-7 [30].
Almost no enrichment was observed of this gene set in
MDA-MB-231 cells after treatment with any of the
compounds (HKMTI-1-005, GSK343 and UNC0638)
(Fig. 4a), suggesting that EZH2 has cell-type-specific
targets. To investigate this further, we undertook a
meta-analysis to identify consensus target genes based
on 18 independent EZH2 siRNA studies (details of the
meta-analysis are provided in ‘Methods’ also see
Additional file 4: Table S5). Encouragingly, treatment
of MDA-MB-231 cells with HKMTI-1-005 resulted in
highly significant upregulation of these consensus
EZH2-repressed genes (Fig. 4a). This suggests that key
EZH2 target genes that are conserved across a wide
range of cell lines are re-expressed upon treatment with
our dual HKMT inhibitor. Furthermore, this identifies
Fig. 4 Compound-induced upregulation of EZH2-repressed target genes. a Enrichment scores for differential expression of EZH2 targets on
treatment with panel of compounds. Enrichment scores are negative logarithm of p values, such that higher values indicate more significant
enrichment. Left-hand bars show enrichment of targets derived from siRNA knockdown of EZH2 in MDA-MB-231 cell line (labelled ‘Lee EZH2
target upregulation’), middle bars show enrichment of targets derived from siRNA knockdown of EZH2 in MCF7 cell line (labelled ‘Tan EZH2
target upregulation’) and right-hand bars show enrichment of targets defined by meta-analysis of 18 independent microarray studies profiling
effects of shRNA-mediated EZH2 knockdown in a variety of cell lines (labelled ‘Meta EZH2 target upregulation’): See ‘Materials and Methods’. b Sybr
green real-time PCR mRNA level measurement of EZH2 target genes and executing enzymes following a 48-h treatment with HKMTI-1-005 at different
concentrations of MDA-MB-231 cells. c Sybr green real-time PCR measurement of the SPINK1 transcription start site following chromatin
immunoprecipitation, using antibodies to the histone marks shown, of MDA-MB-231 cells treated with HKMT-I-005 or HKMT-I-011 at 2.5 μM for
24 h. Each IP-value has been determined as the relative increase to the no-antibody control and is shown as fold difference relative to the untreated
control. d Western blot showing levels of modified histones, following a 48-h treatment with HKMTI-1-005 at different doses. Total H3 levels are shown
for comparison. e Densitometry quantification of Western blot intensity, showing ratio of modified (H3K27me3 top, H3K9me3 bottom) H3 relative to
total H3 with increasing dose of HKMTI-1-005 treatment
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EZH2 inhibitors across cell types.
Compound-induced changes in H3K9me and H3K27me
levels in cells
The microarray data showed a clear upregulation of the
levels of SPINK1 mRNA (a gene previously identified as
a target for dual EZH2 and EHMT2 inhibition, see Fig. 1)
following treatment with HKMTI-1-005, an observation
that was confirmed via qRT-PCR (Fig. 4b). These qRT-
PCR experiments demonstrated a dose-dependent up-
regulation of SPINK1 alongside a re-evaluation of the
candidate genes (KRT17, FBX032, JMJD3) chosen forTable 2 Cell growth IC50 of HKMT inhibitors in MDA-MB-231 cells
Cell growth assay (IC50 μM) HKMT-1-005
Cell viability (MTT) 4.3
Clonogenic 0.41
IC50s (μM) for the dual inhibitor compounds HKMT-1-005 and HKMT-1-011 in cell v
to the starting point for the chemical library BIX-01294, as well as UNC0638 and GSthe initial compound screen. Furthermore, ChIP-PCR at
the SPINK1 transcription start site clearly demonstrated
a reduction in both H3K27me3 and H3K9me3 in MDA-
MB-231 cells after treatment with 2.5 μM HKMT-I-005
(Fig. 4c). More broadly, Western analysis showed that
global levels of H3K27me3 and H3K9me3 are reduced
in MDA-MB-231 cells after treatment with HKMTI-1-
005 (Fig. 4d), and densitometry analysis (Fig. 4e) sug-
gests this happens in dose-dependent manner. Together,
these data strongly support that the hit compound
HKMT-I-005 reduces levels of H3K27me3 and H3K9me3
at concentrations of compound that are less or equivalent
to the growth inhibition IC50 concentration for MDA-BIX-01294 UNC0638 GSK343
9.6 8.2 >15
1.4 1.1 >50
iability (MTT assay) or clonogenic growth assays of MDA-MB-231 cells compared
K343
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global levels of H3K27me3 and H3K9me3 in MDA-MB-
231 cells was performed following treatment with
GSK343 and UNC0638 as single agents and in combin-
ation (Additional file 1: Figure S1).
In order to identify specific pathways being transcrip-
tionally modulated, the microarray data was analysed for
enrichment of pathways belonging to each pathway listed
on the ConsensusPathDB (CPDB) database [36]. The
Benjamini-Hochberg-adjusted [37] enrichment p value es-
timates for each treatment is given in Additional file 5:
Table S6. Interestingly, genes belonging to the pathway
‘Apoptosis’ displayed a highly significant systematic
shift towards upregulation on treatment with our hit
compound(s) at 24 h (p < 1E-4) but not the selective
EZH2 (GSK343) or EHMT2 (UNC0638) inhibitor com-
pound (p = 0.42 and p = 0.30, respectively). Consistent
with induction of apoptosis-related genes, hit compound
HKMTI-1-005 induces apoptosis in MDA-MB-231 cells
in a dose-dependent manner, as measured by Caspase 3/7
activity (Additional file 6: Figure S2).
Cell growth inhibition induced by HKMT inhibitors
The IC50 of the dual inhibitor compounds HKMT-1-
005 in cell viability (MTT assay) or clonogenic growth
assays of MDA-MB-231 cells compared to the starting
point for the chemical library BIX-01294, as well as
UNC0638 and GSK343, are shown in Table 2. Encour-
agingly, the dual inhibitors show greater inhibition of
cell growth as measured both by cell viability and clono-
genic assay compared to the EHMT2- or EZH2-specific
inhibitors. EZH2 inhibitors are reported to be particu-
larly effective at inhibiting cell growth of cell lines with
mutant EZH2 [11, 12]. Indeed, the DB lymphoma cell
line which has an EZH2 mutation (Y646N, according to
the COSMIC database [38]) was observed to be particu-
larly sensitive to the EZH2 inhibitor GSK343 (Table 3).Table 3 Cell growth IC50 inhibitors in a panel of cell lines
(A) Lymphoma cell lines
EZH2 status WSU-
FSCLL
WILL1 DOHH2 SC1 DB SUDLH8
HKMT-I-005 3.405 5.599 3.257 3.711 <1 <1
GSK343 2.868 17.91 6.151 12.12. <1 5.11
W.T. W.T. W.T. W.T. Mutant
Y646N
W.T.








HKMT-I-005 4.3 7.7 8.5 2.1 7.7 >15
Cell growth IC50s (in μM) for a panel of cell lines, after treatment with HKMT-I-
005 or GSK343: lymphoma cell lines (A), derived from cell counting following
propidium iodide staining, and breast cancer cell lines (B), derived from MTT
assays for cell viability. Mutation status of EZH2 is shown for each of the
lymphoma cell linesConsistent with the hit compounds having gained EZH2
inhibitory activity, DB cells were also found to be sensi-
tive to HKMTI-1-005. GSK343 was found to be less
potent on all the other lymphoma lines, which express
wild type EZH2, with anti-proliferative effects observed
at micromolar concentrations of compound treatment.
This included the cell line SUDLH8, which has amplified
and highly expressed wild type EZH2 (processed data
obtained from the Cancer Cell Line Encyclopedia [39]).
Interestingly, SUDLH8 is more sensitive to HKMTI-1-005
than the other lymphoma lines with WT EZH2 (Table 3),
suggesting that increased sensitivity to this dual inhibitor
will not be dependent on cancer cells carrying activating
mutations but perhaps any mechanism of increased de-
pendency on EZH2.
The anti-proliferative effect of HKMTI-1-005 on a
small panel of breast cancer cell lines was determined,
with IC50 values in the range 2–10 μM (Table 3). All of
the cancer breast cell lines examined were found to be
more sensitive to HKMTI-1-005 compared to a normal
breast epithelial cell line MCF10a. The breast cancer cell
line BT-474, which is the cell line most sensitive to
HKMTI-1-005 treatment, has the highest relative expres-
sion of EZH2, as detected by Western analysis (data not
shown).Hit compounds directly inhibit EZH2 and EHMT1/2 and
are substrate competitive inhibitors
We have previously reported the EHMT2 IC50 of
HKMTI-1-005, HKMTI-1-011 and HKMTI-1-022 to be
0.10, 3.19 and 0.47 μM, respectively [40]. This data was
generated using a scintillation proximity assay (SPA)
which monitors the transfer of a tritium-labelled methyl
group from [3H]S-adenosyl-L-methionine (SAM) to a
biotinylated-H3 (1–25) peptide substrate, mediated by
EHMT2. A comparable PRC2 enzymatic assay was
employed here to assess biochemical inhibitory activity of
our hits against EZH2. A trimeric PRC2 complex
(EZH2:EED:SUZ12) was employed in this assay, along
with a biotinylated-H3 (21–44) peptide substrate. This re-
vealed HKMTI-1-005, HKMTI-1-011 and HKMTI-1-022
to have PRC2 IC50 values of 24, 12 and 16 μM, respect-
ively, under these assay conditions (see Additional file 7:
Figure S3). Since the peptide substrates used in these
assays are poor models for the complex and dynamic
structure of the chromatin substrate in cells and since the
only minimal number of PRC2 proteins (EZH2:EED:-
SUZ12) required for enzymatically active EZH2 were
employed in the PRC2 assay, care should be taken in the
over interpretation of this in vitro inhibitory data.
Nonetheless, we note that both the EHMT2 and PRC2
biochemical potency is comparable to the inhibitory
concentrations employed in our cell-based assays.
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design rationale, mechanism of inhibition studies on
representative hit HKMTI-1-005 revealed it to have a
well-defined, peptide substrate competitive mechanism
of action (see Additional file 8: Figure S4), in contrast to
all known EZH2 inhibitory chemotypes. Broad screening
of our compound library against PRC2 using this assay re-
vealed the IC50 values obtained for all actives to be
dependent on peptide substrate concentration (data not
shown), further confirming a substrate competitive inhibi-
tory mode for this chemotype.
Finally, a methyltransferase selectivity screen was car-
ried out for the hits on a panel of enzymes including 11
HKMTs, 3 protein arginine methyltransferases (PRMTs)
and 1 DNA methyl-transferase (DNMT) (Additional file
9: Figure S5). None of the hits had any significant inhibi-
tory activity against these 15 other methyltransferase
targets (up to 100 μM), confirming them to be selective
for EZH2 and EHMT1/2. Taken together, these data re-
veal our hit compounds to be dual EZH2 and EHMT1/2
inhibitors with a substrate competitive mechanism of
action.
Discussion
It is widely accepted that the installation, maintenance
and functional output of epigenetic modifications occur in
concert via combinatorial sets of modifications. Therefore,
removal of a single specific repressive mark may not alone
be sufficient for reversal of gene silencing. Elimination of
multiple repressive methylation marks may instead be
required to re-express a wider spectrum of genes. Given
the complexities of epigenetic regulation and cross-talk
between epigenetic regulators, the discovery of inhibitors
of epigenetic processes that lead to reversal of epigenetic
silencing may be more suited to cell-based methods meas-
uring reactivation of a panel of target genes, rather than
cell-free assays that use purified components. Through
the use of a breast cancer (MDA-MB-231) cell assay based
on the re-expression of epigenetically silenced genes, we
report the identification of hit compounds that phenocopy
the effects of dual EZH2/EHMT2 pharmacological inhib-
ition and dual SiRNA gene knockdown.
The recently reported specific EZH2 inhibitors are all
co-factor competitive, the majority of which have con-
verged to a common chemotype (Fig. 2) [10–16]. Con-
versely, the dual EZH2/EHMT2 inhibitors we here report
are substrate competitive. Not only do these represent the
first inhibitors uniquely targeting the substrate binding
site of EZH2 but also confirm our original hypothesis that
the histone-binding sites of certain HKMTs are similar
[33], and it is therefore possible to discover dual inhibitors
targeting this supposedly divergent pocket. Indeed, the re-
sults herein suggest that there are common aspects to the
histone-binding pockets of the repressive HKMTs, EZH2and EHMT1/2, different from other HKMTs. Indeed, our
selectivity data suggest EZH2 and EHMT1/2 to be the sole
HKMT targets of our hit compounds, as does our cell-
based data. It is interesting that small changes to the
chemical structure of these molecules endow our hits
with dual activity, something not observed for the
structurally related UNC0638. Indeed, quinazoline
EHMT2 inhibitors UNC0638 [24] [22] and UNC0642
[25] have been previously shown not to significantly in-
hibit EZH2 in biochemical assays.
Amplification or overexpression of EZH2 has been
observed in a wide range of tumour types [3–8]. Fur-
thermore, it has been proposed that epigenetic dysregu-
lation can be a contributing factor to acquired drug
resistance [7, 8, 41]. In cancers, the specific signalling
mechanisms that lead to rapid tumour cell proliferation
or evasion of drug-induced apoptosis may vary from cell
to cell. One of the appeals of epigenetic therapies in
cancer is that, rather than trying to target each individ-
ual signalling aberration, the target is the means of
acquiring aberrant signalling. Therefore, it is hoped that
such therapies may fare better in a heterogeneous
tumour environment than drugs targeting specific sig-
nalling proteins. In this light, we highlight the observa-
tion that a set of EZH2 target genes derived from siRNA
knockdown in MDA-MB-231 cells were systematically
upregulated following treatment of MDA-MB-231 cells
with HKMTI-1-005, but not a set of EZH2 targets were
identified from siRNA knockdown in MCF7 cells. This
suggests that the compounds are able to elicit a tran-
scriptional response that is specific to a particular cell
line, and thus, represent a means of tailoring the re-
sponse to the targets that are specifically epigenetically
repressed in the cancer cells to be treated. However, this
fact additionally suggests that it may be difficult to find
generally appropriate pharmacodynamics biomarkers
indicative of a cellular response to treatment with the
compounds. To address this, we carried out a meta-
analysis to identify genes with a consistent upregulation
following EZH2 knockdown via siRNA across a panel of
18 cell lines. These genes may reflect useful biomarkers
for extending the drug-screening process into a wider
range of cancer cell lines. We also highlight a potential
biomarker of dual EZH2/EHMT2 inhibition in MDA-
MB-231 cells, the gene SPINK1, which shows no effect
following transfection of siRNA targeting EZH2, nor
siRNA targeting EHMT2, but shows increased expression
following dual transfection of siRNAs targeting EZH2 and
EHMT2. SPINK1 expression is increased upon treatment
with HKMT-I-005, HKMT-I-011 and HKMT-I-022 at
multiple doses and time points. SPINK1, a potent protease
inhibitor, is also known as pancreatic secretory trypsin in-
hibitor (PSTI), and mutations in SPINK1 have been asso-
ciated with chronic pancreatitis [42].
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upregulated upon treatment with HKMTI-1-005 were
more enriched for genes silenced by EZH2 than treatment
with either the specific EHMT2 inhibitor UNC0638 or the
specific EZH2 inhibitor GSK343. It was interesting to note
that the EHMT2 inhibitor UNC0638 seemed to be as
effective as the specific EZH2 inhibitor GSK343 in terms
of specific upregulation of genes silenced by EZH2. This
could in part be explained by the fact that EHMT2 has
the capacity to methylate H3K27 [26, 27] and that rever-
sal of epigenetic silencing of certain EZH2 targets is
dependent on inhibition of EHMT2 [29]. Alternatively,
it could be due to differences in the kinetics of the in-
hibitors that act through different mechanisms, and the
fact that genome-wide expression analysis was only car-
ried out within a limited time window.
We also note that the effects observed on gene expres-
sion, chromatin marks and global levels of H3K27me3
and H3K9me3 occur within 24–72 h, while some previ-
ously reported EZH2 inhibitors only show pharmacody-
namic effects at later time points [10, 12, 14–16]. There
may be many reasons for these differences, including the
mechanism of action of the dual inhibitors, as well as
their effects on mRNA levels of EZH2 and the H3K27
demethylase JMJD3. However, it should be noted that
the kinetics of effects on gene expression we observe
with the dual inhibitors are similar to the kinetics of ef-
fects on gene expression we observe with double siRNA
knockdown of EZH2 and EHMT2. Also, we observe less
effect of GSK343 on H3K27me3 after a 48-h treatment
of MDA-MB-231 cells compared to previous studies in
ovarian cell line models after 3 days of treatment [43].
This lower activity on H3K27me3 could be cell specific
or due to a shorter treatment period. The wealth of cel-
lular data accumulated for our hit compounds, HKMTI-
1-005 in particular, argue for direct effects on cells at the
target H3K27me and H3K9me modifications at doses of
drug less than or equivalent to growth inhibitory doses.
Such data includes the specific expression of EZH2 target
genes, global histone methylation changes by Western
analysis and local chromatin changes on responsive genes.
We also note the increased sensitivity of the mutant
EZH2 DB lymphoma cell line to HKMTI-1-005, in ac-
cordance with an EZH2 inhibitory effect. Such cellular
biological effects are observed at doses of hit compounds
less than the in vitro biochemical IC50 detected for EZH2.
We would argue that the cellular activity is a consequence
of dual HKMT activity and so extrapolating from single
enzyme IC50 values is difficult. Furthermore, since the
in vitro biochemical EZH2 activity assay conditions used
the minimal number of proteins (EZH2:EED:SUZ12) and
a simple peptide substrate, rather than the complex (and
dynamic) in vivo target of chromatin, care should be taken
in drawing quantitative comparisons with cell-based data.The hit compounds reported herein represent start-
ing points for the further optimisation of dual EZH2/
EHMT2 inhibitors. Indeed, recent reports suggest it is
possible to improve the in vivo profile of this com-
pound class [25]. While this scaffold has been exten-
sively pursued for selective EHMT1/2 inhibition,
further studies are needed to confirm whether it is pos-
sible to simultaneously increase potency against both
EZH2 and EHMT1/2 and whether it is possible to en-
gineer EHMT1/2 activity out of this scaffold to identify
a selective substrate competitive EZH2 inhibitor. None-
theless, it will continue to be important to ‘repurpose’
existing HKMT inhibitor chemotypes, in light of the
low number of validated HKMT inhibitory chemotypes
currently available [16].Conclusions
Many cancers show aberrant silencing of gene expression
and overexpression of histone methyltransferases, in-
cluding EZH2 and EHMT1/2. We have shown that com-
bined inhibition of EHMT1/2 and EZH2 increases
growth inhibition in tumour cells over inhibition of only
EHMT1/2 or EZH2 and results in re-expression of si-
lenced genes. We report the first dual EZH2-EHMT1/2
substrate competitive inhibitors and show that they may
have greater activity in tumour cells that overexpress
wild type EZH2.Methods
qRT-PCR measurements for cell-based screening
Following compound treatment of MDA-MB-231 for
48 h (in 6-well plates), media was removed and 1.5 ml of
TRIzol (Invitrogen) was added directly to lyse cells and
RNA was isolated according to the manufacturer’s in-
structions. Reverse transcription was done using the
SuperScript III First-Strand Synthesis System (Invitro-
gen) according to the manufacturer’s instructions. Each
measurement was done in triplicate, and the List of
Primers can be found in Additional file 2: Table S1. For
normalisation, we have used GAPDH and RNA pol II.
Experiments were also done with the ‘Fast Sybr Green
Cell-to-CT™-Kit’ according to the manufacturer’s in-
structions (Applied Biosystem). Fifteen thousand cells
per 96 well were plated, and after 24 h, treated with
compounds at various concentrations.SiRNA experiments
SiRNA experiments were carried out on the MDA-MB-
231 cell line using Qiagen reagents, according to the
manufacturer’s instructions. In brief, cells were seeded at
a density of 1 × 105 cells/6 cm well and treated for 48 h
with siRNAs given in Additional file 2: Table S2.
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ChIP was accomplished using Dynabeads Protein A
(Invitrogen) according to [44], except that following the
Chelex-DNA purification, an additional purification with
QIAquick PCR Purification Kit (Qiagen) was carried out;
here, the ChIP-products were eluted in 50 μl and for
subsequent qPCR measurements (as described above).
The list of Primers can be found in Additional file 2:
Table S3. Results were calculated as a fold increase of
the no-antibody control and then normalised to GAPDH
(active marks) and beta-globin (inactive marks).
Cell viability assay
For clonogenic assays, cells were treated with compound
for 48 h, media were removed and replaced with fresh
media for a further 12 days to measure colony forma-
tion. For cell viability assays, lymphoma cells were plated
at 20,000 cells in 200 μl per well in U-bottom 96 well
plates in RPMI medium +20 % FCS. Cells were re-
suspended 48 h later, diluted 10-fold in PBS + propidium
iodide (PI) and the concentration of PI negative cells
was counted using an Attune flow cytometer with auto-
sampler. Breast cancer cells were seeded at a density of
10,000 cells/well in a sterile 96 clear-well plate with
150 μl of DMEM (+10 % FCS and 2 mM L-Glutamine).
Each compound treatment was performed in triplicate
for 72 h at concentrations of 100 nM and 1, 5, 10 and
50 μM in 100 μl of full-medium. After 72 h, 20 μl of
MTT solution (3 mg of MTT Formazan, Sigma/1 ml
PBS) was added to the medium and incubated for 4 h at
37 °C in a CO2 incubator. The MTT-product was solubi-
lised with 100 μl DMSO, and for 1 h, incubated in the
dark at room temperature. The optical density was read
at 570 nm with PHERAstar.
Westerns
MDA-MB-231 cells seeded in 6 well plates at a cell density
of 3 x 105 were treated with HKMTI-1-005 (1–7.5uM) for
48 h. Following lysis in Triton Extraction Buffer (TEB,
PBS containing 0.5 % Triton ×100 (v/v), 1/1000 protease
inhibitor), nuclei were re-suspended in 0.2 N HCL at a
density of 4 x 107 nuclei per millilitre and incubated over-
night at 4 °C to acid-extract the histones, before being
centrifuged at 6500g for 10 min at 4 °C. Protein concen-
tration was determined using the Bradford assay.
H3K27me3, H3K9me3, H3K9me2, H3K9me and total H3
protein expression levels in the histone extract samples
were determined using Western blot analysis using
H3K27me3 (1:1000; Abcam), H3K9me3 (1:1000; Abcam),
H3K9me (1:1000) and H3 (1:2000; Abcam) antibodies.
After washing, the membrane was incubated with a horse-
radish peroxidase-labelled secondary antibody (1 h, room
temperature). The membrane was incubated for 1 min
with 5 mL of Pierce ECL Western blotting substrate(Thermo Scientific). Images were captured using Konica
Minolta SRX101ATabletop X-Ray film processor.
Gene expression microarrays
Agilent 80k two-colour microarrays were used to pro-
file gene expression changes induced by treatment with
drug compounds in MDA-MB-231 cells, both at 24 and
48 h. In the initial microarray experiment, three repli-
cates were used for each drug, time combination, and
in the validation study, four replicates were used. A
separate untreated control sample was used for com-
parison with each replicate. Sample labelling, array
hybridization and scanning were performed by Oxford
Gene Technologies, according to manufacturer’s in-
structions. Feature extracted files were imported into
GeneSpring (Agilent), and data was normalised to pro-
duce log2 ratios of treated/untreated for each replicate
of each drug, time combination.
Statistical analysis
Differential expression
Normalised log2 gene expression ratios were analysed
using LIMMA [45] to obtain empirical Bayes-moderated
t statistics for differential expression across the replicates
for each drug treatment. After multiple testing adjust-
ments by the Benjamini-Hochberg method, p < 0.1 was
used to denote significant differential expression in the
initial microarray experiment and p < 0.05 in the valid-
ation experiment.
Enrichment analysis
A list of EZH2 targets in MDA-MB-231 cells were
taken from [35]. Statistical significance of systematic
upregulation or downregulation of these targets was
evaluated using the ‘GeneSetTest’ method from the
Bioconductor package limma. The same method was
used to evaluate systematic up- or downregulation of
pathways as annotated in ConsensusPathDB [36]. Fur-
ther analysis was performed using DAVID [46] for
exploration of functional annotation enrichments.
Identification of a set of consensus EZH2-suppressed
genes via meta-analysis
A meta-analysis of 18 microarray experiments were car-
ried out as described in ‘Supplementary Methods’, result-
ing in the list of consensus EZH2 target genes given in
Additional file 3: Table S4.
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